SAN.PA SANOFI
Healthcare · Drug Manufacturers - General
78.56
+1.15%
About the company
Sanofi engages in the research, development, manufacture, and marketing of therapeutic solutions. It provides immunology and inflammation, rare diseases neurology, oncology, and other vaccines. It also offers poliomyelitis, pertussis, and haemophilus influenzae type b (Hib) pediatric vaccines; respiratory syncytial virus protection and hexavalent combination vaccines that includes hepatitis A, typhoid, yellow fever, and rabies vaccines. It has a collaboration and license agreement with Exscientia to develop up to 15 novel small-molecule for oncology and immunology; ABL Bio, Inc. to develop ABL301 for treatment of alpha-synucleinopathies; and Innate Pharma SA for cell engager program targeting B7-H3. Further, it has a collaboration agreements with Atomwise to use ATOMNET platform and Insilico Medicine to use Pharma.AI, a medicine's AI platform; Kymera Therapeutics, Inc. to develop and commercialize protein degrader therapies targeting IRAK4 in patients with immune-inflammatory diseases; Nurix Therapeutics, Inc. to develop protein degradation therapies; Denali Therapeutics Inc. to treat systemic inflammatory diseases, such as ulcerative colitis; and Adagene Inc. for development of antibody-based therapies. Additionally, it has a collaboration with Scribe Therapeutics Inc. to develop genome editing technologies; Teva Pharmaceuticals to co-develop and co-commercialize TEV'574, for treatment of ulcerative colitis and Crohn's disease; and co-promotion service agreement with Provention Bio, Inc. for the commercialization of teplizumab. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was incorporated in 1994 and is headquartered in Paris, France.
52-week range
Dividend deep dive
SANOFI (SAN.PA) is a pharmaceutical company in the Drug Manufacturers - General industry within the Healthcare sector. The company currently offers a dividend yield of 5.33%. This yield is above its five-year historical range, where the highest yield was 4.48% and the average was 3.92%. SANOFI has a dividend rating score of 6.0, and its dividend safety is currently classified as "at_risk."
Dividend history
SANOFI has a record of 20 consecutive years of dividend increases, earning it a "Contender" status in the CCC list. The dividend has grown with a 3-year compound annual growth rate (CAGR) of 5.587% and a 5-year CAGR of 4.470%. Recent annual dividends paid include EUR 3.03 in 2018, EUR 3.07 in 2019, EUR 3.15 in 2020, EUR 3.20 in 2021, EUR 3.33 in 2022, and EUR 3.56 in 2023. Projected dividends for 2024 and 2025 are EUR 3.76 and EUR 3.92, respectively. The company pays dividends annually in May.
Dividend safety
SANOFI's dividend safety is classified as "at_risk," primarily due to a payout ratio of 104.04%. The company's leverage, reflected by a debt-to-equity ratio of 27.372%, appears moderate.
Quantic · Free
Read the rest of the safety verdict
Plus the key risks and what to watch next — free, no card.
AI-generated from Quantic's dividend data · Updated 17 Jul 2026 · Information, not financial advice.
Price history
Dividend profile
Yield band A stock's current dividend yield shown against its own range over the past five years — the low, average and high. Near the high end the shares look relatively cheap for the income they pay; near the low end, relatively expensive. It's the picture behind Dividend Yield Theory. Learn more → (5-year)
Payment calendar
Dividend history
Per-share dividend by year
Debt & leverage
Latest reported balance-sheet figures.
Held by 2 investors · watched by 1
Appears in these lists
SAN.PA qualifies for these curated dividend rankings.
New to dividend investing?
Information, not financial advice.
Quantic · Free
Track SAN.PA and your whole portfolio
Real yield, dividend safety, net-of-tax income and your path to freedom — free, no broker connection.
Need more? Pro adds portfolios, options income tracking & more AI. See Pro →